Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Patch Clamp01:18

Patch Clamp

5.6K
Many fundamental cell functions such as muscle contraction and nerve transmission rely on the electrical signals produced by the movement of positively and negatively charged ions across the cell membrane. One competent method to record current flowing across the whole cell or single ion channel is the patch-clamp technique.
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...
5.6K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drug Nomenclature01:17

Drug Nomenclature

1.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Science quality and the value of inventions.

Science advances·2019
Same author

Countering European brain drain.

Science (New York, N.Y.)·2017
Same author

Reviewers are blinkered by bibliometrics.

Nature·2017
See all related articles

Related Experiment Video

Updated: Jul 23, 2025

Microfabrication of Implantable Optics Integrated in a Microstructured Imaging Window for Advanced In Vivo Imaging
07:14

Microfabrication of Implantable Optics Integrated in a Microstructured Imaging Window for Advanced In Vivo Imaging

Published on: April 11, 2025

660

New options for patenting in Europe.

Reinhilde Veugelers1, Dietmar Harhoff2

  • 1Reinhilde Veugelers is a professor at KU Leuven, Leuven, Belgium; a senior fellow at Bruegel, Brussels, Belgium; and a senior fellow at the Peterson Institute for International Economics, Washington, DC, USA.

Science (New York, N.Y.)
|July 13, 2023
PubMed
Summary

Inventors in participating European Union countries can now choose between the new unitary patent (UP) system or traditional European patents. This choice aims to strengthen the pan-European patent landscape, pending wider adoption of the UP system.

More Related Videos

Perspectives on Neuroscience
00:26

Perspectives on Neuroscience

Published on: July 31, 2007

5.0K
Fabrication of Carbon-Based Ionic Electromechanically Active Soft Actuators
14:42

Fabrication of Carbon-Based Ionic Electromechanically Active Soft Actuators

Published on: April 25, 2020

8.3K

Related Experiment Videos

Last Updated: Jul 23, 2025

Microfabrication of Implantable Optics Integrated in a Microstructured Imaging Window for Advanced In Vivo Imaging
07:14

Microfabrication of Implantable Optics Integrated in a Microstructured Imaging Window for Advanced In Vivo Imaging

Published on: April 11, 2025

660
Perspectives on Neuroscience
00:26

Perspectives on Neuroscience

Published on: July 31, 2007

5.0K
Fabrication of Carbon-Based Ionic Electromechanically Active Soft Actuators
14:42

Fabrication of Carbon-Based Ionic Electromechanically Active Soft Actuators

Published on: April 25, 2020

8.3K

Area of Science:

  • Intellectual Property Law
  • European Union Policy
  • Innovation Management

Background:

  • A new unitary patent (UP) system has been implemented across select European Union (EU) member states.
  • This system offers an alternative to the existing European patent route for inventors.
  • The UP system aims to streamline patent protection across multiple EU countries.

Discussion:

  • The introduction of the unitary patent (UP) system presents inventors with a strategic choice between two distinct intellectual property protection routes.
  • This dual-path approach is designed to foster a more dynamic and comprehensive patent landscape within Europe.
  • The success of the unitary patent (UP) system hinges on its widespread adoption by EU member states and inventors.

Key Insights:

  • Inventors now have a choice between the unitary patent (UP) and traditional European patents in participating EU countries.
  • The UP system is intended to create a more unified and robust pan-European patent framework.
  • Widespread adoption is crucial for the unitary patent (UP) system's long-term effectiveness.

Outlook:

  • Future developments will focus on the adoption rates and practical implications of the unitary patent (UP) system.
  • The interplay between the UP system and existing European patents will shape the future of intellectual property in Europe.
  • Potential for enhanced cross-border innovation and market access through streamlined patenting.